Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 14/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.76 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.76 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.76 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.76 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2447372 | 0.90 | MTOR (0.63) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1311948 | 0.88 | PIK3CA (0.71) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1309466 | 0.86 | PIK3CA (1.00) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL29879988 | 0.86 | PIK3CA (1.00) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL856368 | 0.85 | MTOR (0.60) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL10198065 | 0.84 | MTOR (0.61) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL10327728 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL29627295 | 0.83 | MTOR (1.00) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL1309362 | 0.83 | MTOR (0.76) | MTORPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL855868 | 0.83 | PIK3CA (0.68) | MTORPIK3CAPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | claimed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | claimed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | claimed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | claimed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | claimed |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2022-05-05 | — | — | US | disclosed |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2021-11-25 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-10993947-B2 | Treatment of skin lesions | TORQUR (CH) | 2021-05-04 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | CXCR3, C3AR1, CCR3 | MTOR 4061/4885PIK3CA 3770/4885PIK3CB 4445/4885 |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3CB 12/4885 |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | MTOR 4473/4885PIK3CA 4513/4885PIK3CB 4670/4885 |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | MTOR 64/4885PIK3CA 5/4885PIK3CB 8/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | MTOR 2949/4885PIK3CA 426/4885PIK3CB 769/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | MTOR 2086/4885PIK3CA 1228/4885PIK3CB 1318/4885 |
| US-10993947-B2 | Treatment of skin lesions | CXCR3, CCR3, C3AR1 | MTOR 4107/4885PIK3CA 3971/4885PIK3CB 4669/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | MTOR 2/4885PIK3CA 1/4885PIK3CB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.